Navigation Links
Triple Negative Cancer Research Could Benefit All Breast Cancer Patients
Date:1/31/2011

FREDERICKSBURG, Va., Jan. 31, 2011 /PRNewswire/ -- Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.

"Understanding how triple negative cancers spread in the absence of normal growth factors may give us insight into how other types of breast cancer grow and spread even after treatment," Dr. Tucker explains.

Recent research has shown that a new class of drugs, PARP inhibitors, can be combined with chemotherapy to kill more triple negative breast cancer cells. Research also indicates that platinum compounds, a type of chemotherapy not typically prescribed for breast cancer, may be useful in treating triple negative disease.

Currently, two trials offered at Fredericksburg Oncology focus on triple negative disease.

  • CALGB 40603:  Pre-operative (neoadjuvant) chemotherapy for triple-negative breast cancer involving platinum chemotherapy (carboplatin) and bevacizumab.
  • NCCTG N0937:  Platinum chemotherapy (Cisplatin) and brostacillin for metastatic triple-negative breast cancer

An estimated 15 percent of breast cancers are triple negative, meaning they do not have receptors for estrogen, progesterone, and for the growth factor receptor HER2.  Breast cancer treatments such as Tamoxifen, Arimidex, Femara, and Herceptin which target these molecules are therefore not helpful against triple negative disease. Standard chemotherapies can be used in triple negative breast cancer, but they may not be as effective as they are for more common breast canc
'/>"/>

SOURCE Fredericksburg Oncology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
2. Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
4. By 2019, the Acute Gout Drug Market Will Triple in Size While the Chronic Gout Drug Market Will Reach $1.83 Billion
5. The Hepatitis C Virus Drug Market Will More Than Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
6. The Hepatitis C Virus Drug Market Will Nearly Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
7. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
8. EndoChoice® Triples Facility Space to Address Growing Customer Base
9. New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
10. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
11. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... the "Medical Oxygen Systems - Global Strategic Business ... report analyzes the worldwide markets for Medical Oxygen Systems ... Liquid Oxygen Systems, Oxygen Cylinders & Regulators, and Oxygen ... the US, Canada , ...
(Date:4/17/2015)... Steven Rash , the CEO of Algae International Group, ... Seed & Oil Company, presented the Company,s latest developments ... York City.  Mr. Rash,s presentation featured the Company,s Product ... Company has recently announced the Dube Hemp Energy ... the EpiVape , and Hempster Clothing .  ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/7qs3dw/corporate ) has announced ... in 2014 - a Perspective of Diabetes Patient Groups ... This independent study, funded by the author, represents ... in diabetes on the corporate reputation of 14 individual ... whole) in 2014. The results from the respondent diabetes ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
(Date:4/18/2015)... 2015 Insuranceautoquote.info has released a new ... insurance quotes . , Clients can review important ... The online environment provides important advantages for clients who ... Drivers who do not have coverage for their vehicles ... season, day or hour. Many agencies offer important discounts ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
(Date:4/18/2015)... 2015 Aureus Medical Group (web: ... physical therapy jobs, has announced that it will ... Physical Therapy Association Annual Conference to be held ... Greenville, SC. , The SCAPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
(Date:4/17/2015)... 2015 Riviera Magazine has ... of the Gallery of Cosmetic Surgery in Newport ... experts. The publication focused on his expertise in ... fat grafting, eyelid surgery, laser resurfacing and rhinoplasty. , ... has resulted in thousands of satisfied patients across ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... cerebrovascular disease , MONDAY, Dec. 10 (HealthDay News) -- ... for mild cognitive impairment, says a study by researchers ... City. , Mild cognitive impairment, which causes learning and ... years, particularly as a means of identifying the early ...
... team of researchers from the University of Pennsylvania School ... in the immune system process that fights infection yet, ... tissue., The Penn team, led by Christopher Hunter, chair ... identified the pathways that lead to the production of ...
... Although psychiatrists are among the least religious physicians, they ... and spiritual dimensions of their patients, according to survey ... Journal of Psychiatry. , Ever since Freud described religious ... been tension and at times hostility between religion and ...
... problems with Prilosec and Nexium , , MONDAY, Dec. ... of the popular heartburn drugs Prilosec and Nexium found ... Monday. , The announcement followed a three-month safety review ... preliminary studies. But detailed data from both studies, plus ...
... Dec. 10 JPMorgan,s Annual,Healthcare Conference, which celebrates ... 7-10 at the Westin St. Francis Hotel in ... largest, will feature,presentations from approximately 300 companies, both ... This year,s event will include,panel discussions with leading ...
... mg, * 53% of Patients Treated with 90 mg Dose ... in the Risk of Death ... Compared to Non-responders, ATLANTA, Dec. 10 Pharmion ... data,from the Phase 1/2 study investigating the combined use of MGCD0103, a,novel, ...
Cached Medicine News:Health News:Hypertension Linked to Risk of Mild Cognitive Impairment 2Health News:Researchers led by Penn vet uncover the delicate protein balance behind the immune system response 2Health News:Psychiatrists: Least religious but most interested in patients' religion 2Health News:Psychiatrists: Least religious but most interested in patients' religion 3Health News:Psychiatrists: Least religious but most interested in patients' religion 4Health News:FDA Confirms No Heart Risk From Heartburn Drugs 2Health News:FDA Confirms No Heart Risk From Heartburn Drugs 3Health News:JPMorgan's 26th Annual Healthcare Conference Media Advisory 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: